| 1 | 2011 Pipeline of Seattle Genetics. | 
                        
                | 2 | Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467. | 
                        
                | 3 | ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies | 
                        
                | 4 | J Clin Oncol 32:5s, 2014 (suppl; abstr 2558). | 
                        
                | 5 | Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3. | 
                        
                | 6 | Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106. | 
                        
                | 7 | SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647. | 
                        
                | 8 | ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | 
                        
                | 9 | National Cancer Institute Drug Dictionary (drug id 721679). | 
                        
                | 10 | Clinical pipeline report, company report or official report of Seagen. | 
                        
                | 11 | Clinical pipeline report, company report or official report of CRISPR Therapeutics. | 
            
            
                |  |  |  |  |  |  |